Cell therapy weekly: Lynch Regenerative Medicine, Inc. launched to address regenerative therapies for skin conditions
This week: The launch of Lynch Regenerative Medicine, Inc. (TN, USA) will target underserved skin conditions, FibroBiologics (TX, USA) dedicates its new lab to the development of cell therapies and a collaboration of MaaT Pharma (Lyon, France) and Skyepharma (Saint-Quentin-Fallavier, France) has culminated in the completion of largest cGMP microbiome therapy manufacturing facility in Europe.
The news highlights:
- Lynch Regenerative Medicine, Inc. launched to address regenerative therapies for skin conditions
- FibroBiologics inaugurates new laboratory facility as the Newlin-Linscomb Lab for Cell Therapeutics
- MaaT Pharma and Skyepharma complete construction of Europe’s largest manufacturing facility for microbiome therapies
Lynch Regenerative Medicine, Inc. launched to address regenerative therapies for skin conditions.
Samuel Lynch, a serial biotechnology entrepreneur who has previously founded companies like Lynch Biologics and BioMimetic Therapeutics (both TN, USA), has launched Lynch Regenerative Medicine, Inc. Using their patented technology, rhPDGF (Manufactured Platelet-Derived Growth Factor), they will target the treatment of underserved skin conditions for both aesthetic and advanced wound care applications.
“I am thrilled to announce the formation of Lynch Regenerative Medicine,” said Lynch. “Skin is the largest organ in the body, and is therefore our biggest opportunity yet to utilize the powers of rhPDGF to improve the emotional and physical health of people around the world. By harnessing the power of our highly successful regenerative technology to naturally stimulate growth of the person’s own stem cells, we have the potential to revolutionize both cosmetic and prescription-strength skin therapies and thereby help millions of patients attain healthier, more attractive appearance and heal skin injuries faster.”
FibroBiologics inaugurates new laboratory facility as the Newlin-Linscomb Lab for Cell Therapeutics
FibroBiologics, a clinical-stage biotechnology company, has dedicated its new laboratory facility at the University of Houston Innovation Centre (TX, USA) to the development of cell therapeutics. The laboratory, inaugurated as the Newlin-Linscomb Lab for Cell Therapeutics, will enable FibroBiologics to pursue the development of fibroblast and fibroblast-derived therapies.
Hamid Khoja, Chief Scientific Officer of FibroBiologics stated: “The opening of this new laboratory represents the next stage in the development of our novel and effective fibroblast therapies. Our excitement is high as our scientific team prepares to utilize this new facility to the fullest.”
MaaT Pharma and Skyepharma complete construction of Europe’s largest manufacturing facility for microbiome therapies
MaaT Pharma, a clinical-stage biotechnology company, and Skypharma, a French independent CDMO, have announced the completion of the largest cGMP facility in Europe for the manufacture of full ecosystem microbiome therapies. These therapies are designed to restore the microbial ecosystem in patients with graft-versus-host disease, a serious complication of haematopoietic stem cell transplantation.
MaaT Pharma and Skyepharma are currently performing quality qualification according to GMP guidelines, with the first production campaign targeted to start in the facility by late 2023.
“This new GMP manufacturing facility is a testament to the continued growth of MaaT Pharma,” stated Hervé Affagard, CEO of MaaT Pharma “Thanks to our strategic partnership with Skyepharma, we have successfully completed the new infrastructure within a year, I also want to take the opportunity to thank the ABL Europe team who have hosted our GMP production since 2016.”
Last weeks news in cell and gene therapy
Lineage and Eterna Therapeutics began the next phase of their strategic partnership, MaaT Pharma’s adjunctive therapy received orphan drug designation, and Kriya’s acquires Tramontane.
